行情

OPGN

OPGN

OpGen
NASDAQ

实时行情|Nasdaq Last Sale

1.061
-0.045
-4.03%
交易中 13:52 11/19 EST
开盘
1.130
昨收
1.105
最高
1.130
最低
1.050
成交量
20.10万
成交额
--
52周最高
40.60
52周最低
0.9200
市值
592.00万
市盈率(TTM)
-0.0434
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

OPGN 新闻

  • OpGen Products in Development to Address “Urgent Threat” Pathogens Highlighted in New CDC Report on Antibiotic Resistance Threats
  • GlobeNewswire.6小时前
  • The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
  • Benzinga.4天前
  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.5天前
  • Edited Transcript of OPGN earnings conference call or presentation 6-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.5天前

更多

所属板块

生物技术和医学研究
+2.05%
制药与医学研究
+0.69%

热门股票

名称
价格
涨跌幅

OPGN 简况

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
展开

Webull提供OpGen Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。